Hyoscine Butylbromide PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Blocks muscarinic acetylcholine receptors in gastrointestinal, biliary and genitourinary smooth muscle and also has ganglion-blocking activity within the visceral wall. Its quaternary ammonium structure limits entry into the central nervous system.
Indications / reported uses
Relief of gastrointestinal and genitourinary smooth-muscle spasm
Symptomatic relief of irritable bowel syndrome
Injection products are used for acute spasm such as renal or biliary colic and during selected diagnostic procedures; indication depends on formulation
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Hyoscine Butylbromide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Hyoscine Butylbromide Permitted Daily Exposure (PDE) report (the Hyoscine Butylbromide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Hyoscine Butylbromide Occupational Exposure Limit (OEL) report (the Hyoscine Butylbromide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.